Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
|ClinicalTrials.gov Identifier: NCT00001871|
Recruitment Status : Completed
First Posted : December 10, 2002
Last Update Posted : March 4, 2008
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle. This condition can cause patients to experience symptoms of chest pain, shortness of breath, fatigue, and heart beat palpitations. Researchers believe the disease may be caused by abnormalities in the genes responsible for producing proteins of the heart muscle.
Oculopharyngeal muscular dystrophy (OPMD) is another genetically inherited disease. This condition affects the muscles of the eyes and throat causing symptoms of weak eye movements, difficulty swallowing and speaking, and weakness of the arms and legs.
In previous studies researchers have found that several patients with hypertrophic cardiomyopathy (HCM) also had oculopharyngeal muscular dystrophy (OPMD). Researchers are interested in learning more about how these two diseases are associated with each other.
In this study, researcher plan to collect samples of muscles (skeletal muscle biopsies) from patients belonging to families in which several members have inherited one or both of these diseases. The muscle samples will be used to link the muscle abnormalities with the specific genetic mutations.
Patients participating in this study may not be directly benefited by it. However, information gathered because of this study may be used to develop better techniques for diagnosing and treating these conditions.
|Condition or disease|
|Cardiomyopathy, Hypertrophic Muscular Dystrophy, Oculopharyngeal|
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||An Exploratory Study of Skeletal Muscle Abnormalities in Patients With Mutations in Alpha-Tropomyosin and PABP2 Genes|
|Study Start Date :||January 1999|
|Estimated Study Completion Date :||March 2001|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001871
|United States, Maryland|
|National Heart, Lung and Blood Institute (NHLBI)|
|Bethesda, Maryland, United States, 20892|